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Abstract 
Although a lot of hard work against cancer to reduces its spread but it still continues 
to kill with abandon. The need for a biomarker for cancer early detection becomes the 
most mind concentrated scientists. MicroRNAs the tiny non coding RNA molecules 
opened new path for the scientists to determine the cancer in its early stages. 
Expression of microRNAs profiles has been investigated to be involved in cancer 
development. Here we determined the expression of microRNAs in serum of Iraqi 
healthy volunteers and other women diagnosed with breast cancer. MicroRNAs 
expression has been determined by using real time qPCR and delta method has been 
used. Four of thirteen microRNAs were shown to be expressed in serum of Iraqi 
breast cancer women. Let-7a and miR-21 were shown to be significantly over 
expressed in serum of breast cancer compared with healthy serum volunteers (P= 
0.022 and 0.026) respectively. While miR-26b and miR-429 found to be significantly 
down expressed in serum of breast cancer women (P= 0.0034 and 0.031) respectively. 
The result concluded that these expressed microRNAs in serum of breast cancer 
women could be used as a first indicator of breast cancer occurrence. 
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Introduction 
Although a lot of hard work against cancer but it still continues to kill with 
abandon [1]. The increase incidence of breast cancer in Iraqi women has been started 
after the Gulf war 1990 and the second war 2003[2]. The need for specific and 
sensitive diagnostic biomarkers for early detection and monitor of breast cancer has 
let the scientists to see; for a marker that predict the breast cancer in an early stages 
[3]. Such biomarker must be sensitive, non-invasive and not affected by 
environmental conditions and may facilitate in early detection and diagnose of breast 
cancer [4]. MicroRNA which are small in size about 23 nt, non-coding RNA 
molecules has been shown to be sequences conserved among plant, animal, human 
and even insect [5]. 
 MicroRNA found to regulate gene expression and involved in biological processes 
including, development, differentiation, proliferation and apoptosis [6]. The function 
of microRNA could be summarized by its binding with the 3'-UTR of the target 
mRNA gene, and by this binding microRNA will target and control the expression of 
that gene [7]. So that microRNA expression profiling may provide a more accurate 
classification of cancer subtypes, diagnosis and prognosis. Micro RNA has been 
shown to be present in human biological fluids (serum/plasma, saliva, tears and urine) 
that will facilitate the diagnosis of disease especially cancer [8]. Current study was 
aimed to determine the expression of microRNAs in serum samples collected from 
Iraqi healthy women and breast cancer diagnosed women. 
Materials and methods 
Serum sample collection 
All women volunteer that participate in current study were interviewed and 
questioned and all information was recorded. Whole blood sample was collected in a 
tube containing gel for serum separation, from healthy women and women diagnosed 
with breast cancer. Blood samples left at room temperature for 30 min. to allow serum 
separation then spun at 1500 g for 10 min. The serum was transferred to a new 
eppendorf tubes and frozen at -80 C until microRNA extraction. 
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MicroRNA extraction 
The circulating microRNAs were extracted from serum samples using microRNA 
extraction kit (Norgen Biotek, Canada) using 200μl of serum aliquots.  All serum 
samples were thawed completely, and then 200μl of serum mixed with denaturation 
buffer in a procedure described in the kit protocol. The microRNA at the end was 
eluted by 50-100 μl of nuclease free water. The microRNA concentration was 
measured using NanoDrop-1000 spectrophotometer (Nano Drop Technologies, USA). 
Reverse Transcription 
The extracted microRNA was reversed transcribed using TaqMan microRNA reverse 
transcription kit (ApplidBiosystems, USA) according to the manufactures protocol. 
Then 5 μl of microRNA was reversed transcribed in a 15 μl reaction volume for each 
assay. 
Real Time PCR  
TaqMan microRNA probes were used (miR-21, let-7a, miR-222, miR-26b, miR-27a, 
miR-15b, miR-34a, miR-34b, miR-205, miR-218, miR-378, miR-429 and miR-191 
was used as an endogenous control) were used to quantify microRNA in real time 
PCR assays according to manufactures protocol. Real time PCR assays were 
performed in a 20 μl reaction volume on a Stratagen 3000p real time system. 
Statistical analysis 
Student t test p value was calculated using GraphPad Prism 6. 
Results  
The microRNAs were isolated from serum of six Iraqi healthy and fifteen breast 
cancer diagnosed women and the expressions of these microRNAs have been 
determined by q-RT-PCR. We selected four miRNAs that statistically significant. We 
found that let-7a and miR-21 expressions was up-regulated in breast cancer patients 
compared with the healthy controls (P= 0.022 and 0.026) respectively as indicated in 
figure (1, A and B respectively; P<0.05) while miR-26b and miR-429 expression 
were down- regulated in breast cancer patients compared with the healthy controls 
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(P= 0.0034 and 0.031) respectively as indicated in figure (1, C and D respectively; 
P<0.05).  
 
 
 
Discussion 
Breast cancer represent the second cancer leading to death in women, is expected 
to be 26% of new cancer diagnosis [9]. The need for specific biomarker for an early 
detection of cancer represents the aim of all scientist work right now. The discovery 
of microRNA in 1993 by lee and coworker opened new sights about these small 
molecules [10], after that in 2008 they found that these tiny RNA molecules are 
circulating of cancer patients followed by a huge number of studies determining 
microRNA importance in early detection of cancers [11]. The detection of some novel 
microRNAs increase the studies attentions. Some of the microRNAs that used in this 
study were detected before and some novels have not been detected before. MiRNAs 
are very stable in blood plasma and serum since protected from RNases [12]. Thus, it 
makes miRNA levels tested for clinical diagnosis as tumor markers and biomarkers. 
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Chim et al., 2008 have suggested two hypotheses for the source of miRNAs on 
circulating blood samples; it may be due to a result of tumor cell death and lyses or 
release by tumor cells into the extracellular microenvironment of blood vessels [13]. 
In this study we analyzed the expression of thirteen microRNAs in serum from fifteen 
breast cancer women patients and six healthy women as controls. Our study showed a 
significant high expression of let-7a and miR-21 in serum of breast cancer patients as 
mentioned in previous studies of Heneghan et al., 2010 and Mar- Aguilar et al., 2013 
[14, 15].   
Let-7a found to be involved in cell proliferation and has role in cancer metastasis 
in various tumors, especially breast cancer [16], our result indicate that let-7a tends to 
be up regulated in serum of breast cancer patients. MiR-21 found to participate in 
regulating the expression of multiple tumor suppressor genes, and played an important 
role in the development of colon cancer, lung cancer, stomach cancer and breast 
cancer [17] like here in current study, miR-21 was up regulated in serum of breast 
cancer patients. MiR-26 has shown to be a key regulator in carcinogenesis and tumor 
progression by acting either as oncogenes or tumor suppressor genes in various 
cancers [18]. MiR-26 is consistently down-regulated in a wide range of malignant 
tumors, such as hepatocellular carcinoma, lung cancer and breast cancer [19]. Breast 
cancer women have down expressed miR-26b in their serums. The miRNA-200 
cluster has been shown to regulate the epithelial-mesenchymal plasticity that may be 
crucial at different stages of metastasis [20].  
It has been suggested that the miR-200 family is a powerful marker and an 
essential regulatory factor of the cancer cell epithelial phenotype [21]. The miR-200 
family of miRNAs consists of five members: miR-200a, 200b and 429 [22]. The 
serum level of miR-429 in breast cancer women was down expressed. The serum 
levels of miR-200a, miR-200b, miR-200c, miR-429, miR-205 and miR-192, and 
urinary miR-200a, miR-200c, miR-141, miR-429 and miR-192 of SLE patients were 
lower than those of controls [23]. The results indicated that there is a possibility of 
detection the changes in the level of microRNAs expression as useful biomarkers for 
the detection and early diagnosis of breast cancer. 
In Conclusion; the significant over expression of let-7a and miR-21 in circulation 
of Iraqi breast cancer women and down expression of miR-26b and miR-429 in the 
same group have been detected and suggested to be new microRNAs in early 
detection of breast cancer.                                                                                                                                       
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